Biotechnology Financing and Partnership News North America · 2d ago

Seawolf Therapeutics Launches With $100 Million and Sanofi Partnership to Advance DNA-Based Medicines in the US

Seawolf Therapeutics launches from stealth with $100M funding and Sanofi deal to advance TRIDENT, its redosable DNA-based LNP delivery platform for new med

RD

Research Desk

· 3 min read

Seawolf Therapeutics Launches With $100 Million and Sanofi Partnership to Advance DNA-Based Medicines in the US

Seawolf Therapeutics, a privately held biotechnology company headquartered in San Diego, California, announced its emergence from stealth with USD 100 million raised to advance its proprietary DNA delivery platform, which the company says is designed to transform patient outcomes.

The seed round was led by founding investor Versant Ventures.

Series A Funding to Advance TRIDENT Therapeutics

The Series A financing was co-led by Versant, MPM BioImpact, and Novartis Venture Fund, with participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures (the philanthropic venture arm of the National Bleeding Disorders Foundation), and others.

The company said the funds will be used to advance its portfolio of therapeutics built on its redosable lipid nanoparticle (LNP)-based DNA delivery system, known as TRIDENT.

Multi-Target Partnership With Sanofi

Alongside the financing announcement, Seawolf unveiled a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications.

Under the terms of the deal, Seawolf is eligible for up to USD 1.2 billion in research, development, and commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration.

"Seawolf is charting a new course in patient care through LNP-based DNA medicines," said Elizabeth Alcamo, Ph.D., president and CEO of Seawolf.

"With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs."

The TRIDENT Platform

The company's technology, TRIDENT (Targeted RNA-Induced DNA Expression via Nuclear Translocation), is a redosable lipid nanoparticle-based DNA delivery system.

According to Seawolf, the platform matches the potency, redosability, safety, and scalability of RNA-based LNP therapies but overcomes their short-lived expression by delivering DNA-based payloads.

The TRIDENT system consists of a proprietary LNP carrying an immune-quiet DNA that encodes a therapeutic transgene, along with an auxiliary factor that facilitates nuclear access. Seawolf says therapies built with the technology are potent, durable, and have a clean safety profile in primates and, unlike virus-based DNA platforms, are redosable, providing the ability to fine-tune or supplement dosing through repeat administration.

The platform has generated sustained protein expression above therapeutic levels in primates at doses that are safe and well-tolerated, according to the company. TRIDENT can be deployed across a broad range of therapeutic areas, including replacing mutant genes and expressing biologics systemically.

Seawolf has demonstrated proof of concept of the technology's applicability in both primates and murine preclinical models of metabolic and rare diseases.

Pipeline and Leadership Outlook

Seawolf's lead proprietary program, targeting metabolic diseases, is advancing to Development Candidate.

"Nucleic acid-based therapies have advanced dramatically over the past decade," said Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf's board of directors.

"The Seawolf team is now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient's own cells. I look forward to seeing this groundbreaking technology transform treatment options for patients."

The company describes its technology as achieving the delivery of DNA into the nucleus of cells to enable long-term, stable expression of therapeutic proteins in a non-immunogenic and redosable format.

In addition to Versant Ventures, MPM BioImpact, and Novartis Venture Fund, Seawolf is backed by Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, and Pathway to Cures.

Tracked in the database

Biotechnology Financing and Partnership News · North America

Category

Biotechnology Financing and Partnership News

Region

North America

Industry

Chemical

Published

16 November 2026

Length

3 min read

Tagged

Lipid Nanoparticle (LNP) TechnologyBiotech FinancingPharmaceutical PartnershipsGene Therapy

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning